---
title: "Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292905923.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-16T09:46:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292905923.md)
  - [en](https://longbridge.com/en/news/292905923.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292905923.md)
generator: "portal-rs"
---

# Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [KAPA.US](https://longbridge.com/en/quote/KAPA.US.md)

## Related News & Research

- [Kairos Pharma CEO John Yu presents at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/298453833.md)
- [HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir](https://longbridge.com/en/news/298763671.md)
- [OpenAI CFO Sarah Friar says ChatGPT's ads should be like 'if Google and Meta had a baby'](https://longbridge.com/en/news/298353501.md)
- [Aptar Pharma to support Aceso’s inhaled cystic fibrosis candidate’s advance](https://longbridge.com/en/news/298273759.md)
- [Snap Could Be 23% Undervalued As New Ad Tools And Leadership Lift Optimism](https://longbridge.com/en/news/298812469.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**